Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various bioph…
Biotechnology
US, New York [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Royalty Pharma plc (RPRX) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 39,072.78 | 13,480.90 | 625.12 | 369.66 | -1,114.21 | 0.00 | 18.0665 | 44.08 | -0.8067 | -20.4751 | -0.08 | -0.07 | 6.4888 | - - | ||
| Maximum | - - | - - | - - | 1,535,067.00 | 609,984.00 | 35,800.00 | 99,050.00 | 5,421.00 | 0.02 | 1,336.3467 | 2,849.43 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -164.8536 | -132.82 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0844 | - - | ||
| CureVac N.V. CVAC | 2.66 | 0.10 3.91% | 473 vs. 471 | 596.00 | 12.00 | -70.00 | -101.00 | -1,636.00 | -0.3100 | -2.2038 | 0.0000 | -2.3694 | -5.7022 | -0.1579 | -0.1022 | 2.0371 | 224.00 | ||
| Royalty Pharma plc RPRX | 26.43 | 0.03 0.11% | 2,377 vs. 2,328 | 11,742.00 | 567.00 | 4.00 | 583.00 | 2,427.00 | 0.0106 | 701.8537 | 0.0070 | -0.0275 | 0.0084 | 0.0007 | 0.0003 | 12.4802 | 444.00 | ||
| Apellis Pharmaceuticals, Inc. APLS | 30.77 | 3.02 10.88% | 2,660 vs. 2,876 | 3,827.00 | 172.00 | -66.00 | -133.00 | -2,903.00 | -0.5400 | -27.6326 | 0.0000 | 0.8802 | -0.3855 | -0.2491 | -0.0798 | 2.7985 | 124.00 | ||
| IVERIC bio, Inc. ISEE | 39.95 | 0.15 0.38% | 10,801 vs. 4,945 | 5,512.00 | 0.00 | -70.00 | -50.00 | -937.00 | -0.5200 | -11.8078 | 0.0000 | 0.0000 | 0.0000 | -0.1480 | -0.1151 | 15.2365 | 137.00 | ||
| Madrigal Pharmaceuticals, Inc. MDGL | 347.45 | 18.21 5.53% | 532 vs. 380 | 7,578.00 | 0.00 | -147.00 | -149.00 | -1,483.00 | -7.3800 | -8.6674 | 0.0000 | 0.0000 | 0.0000 | -0.1734 | -0.1363 | 9.2623 | 21.00 | ||
| Akero Therapeutics, Inc. AKRO | 32.73 | 1.53 4.90% | 824 vs. 549 | 2,284.00 | 0.00 | -53.00 | -35.00 | -627.00 | -0.9000 | -6.6902 | 0.0000 | 0.0000 | 0.0000 | -0.0630 | -0.0585 | 29.8643 | 69.00 | ||
| Karuna Therapeutics, Inc. KRTX | 329.83 | 0.09 0.03% | 1,283 vs. 971 | 12,599.00 | 0.00 | -113.00 | -111.00 | -997.00 | -3.0100 | -26.2644 | 0.0000 | 0.0000 | 0.0000 | -0.0908 | -0.0852 | 18.6075 | 38.00 | ||
| Blueprint Medicines Corporation BPMC | 94.15 | -2.47 -2.56% | 663 vs. 628 | 5,980.00 | 96.00 | 89.00 | -102.00 | -2,250.00 | 1.4500 | 16.6530 | 0.0000 | 0.9168 | 0.9274 | 0.2869 | 0.0858 | 3.4266 | 63.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.